Tenderwize
Retour à la recherche

Open-house pharmaceutical discount agreement for Eribulin

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline May 16, 2027 · 263 days left·Open·Supplies·Framework
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge gemäß § 130a Abs. 8c SGB V Eribulin, ATC L01XX41

62/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

62 / 100

Complexité

58 / 100

Facteurs de risque

Paper submissions require duplicate original signed documents, and electronic submissions require a qualified electroni...

Eligibility is limited to pharmaceutical companies and requires a signed reliability declaration.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Open-house supply arrangement for pharmaceutical products, specifically Eribulin (ATC L01XX41).
  • Non-exclusive discount agreements under § 130a Abs. 8c SGB V for parenteral preparations made from finished medicinal products in oncology.
Afficher le résumé complet

This is an open-house pharmaceutical supply arrangement for Eribulin (CPV 33600000) in Bavaria, not a competitive award procedure. The contracting buyers are led by AOK Bayern, with several other sickness funds participating. Any interested pharmaceutical company may join if it meets the stated eligibility requirement and submits the required signed documents. The contract term runs from 01.08.2025 to 31.07.2027, with applications possible until 16.05.2027. Submission is allowed electronically via DTVP with qualified electronic signature or in paper form by original signed copies.

Risques

Paper submissions require duplicate original signed documents, and electronic submissions require a qualified electroni...

Eligibility is limited to pharmaceutical companies and requires a signed reliability declaration.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Submit a completed and signed self-declaration on reliability (Eigenerklärung zur Zuverlässigkeit).
  • Submit the completed and signed contract and the completed file 'OHV_8c_Bayern_Festlegung_PZN'.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open-house pharmaceutical discount agreement for Eribulin

Open-house, non-exclusive discount agreement for Eribulin (ATC L01XX41) for extemporaneously prepared parenteral oncology preparations for immediate physician use in Bavaria. The notice states that all interested pharmaceutical companies meeting the eligibility condition may conclude identical, non-negotiable agreements. The lot information comes from structured data and notice text.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Germany

Durée

2 YEAR

Catégorie

Pharmaceutical products

Date limite

Deadline May 16, 2027

Détails de la procédure

Date de publication
19 May 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
324154-2025

Documents (2)

Appels d'offres similaires